In addition to their glucose-lowering and cardioprotective effects, recent studies have demonstrated that GLP-1 receptor agonists also provide clinically meaningful benefits in weight reduction, making them a valuable option for patients with type 2 diabetes and coexisting obesity [10]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.